|
Aug 8
|
Nyxoah Receives Approval from FDA for Genio® System for the Treatment of Obstructive Sleep Apnea
|
|
Aug 7
|
Privia Health (PRVA) Misses Q2 Earnings Estimates
|
|
Aug 6
|
Outset Medical, Inc. (OM) Reports Q2 Loss, Beats Revenue Estimates
|
|
Jul 29
|
Nyxoah to Release Second Quarter 2025 Financial Results on August 18, 2025
|
|
Jul 28
|
Nyxoah’s DREAM Pivotal Study Data Published in the Journal of Clinical Sleep Medicine
|
|
Jun 13
|
Invitation to attend the extraordinary shareholders’ meeting of the Company to be held on July 2, 2025
|
|
Apr 16
|
Conditional Issuance of Shares
|
|
Feb 14
|
Hims & Hers Health (HIMS) Surges 27.7%: Is This an Indication of Further Gains?
|
|
Oct 9
|
Nyxoah SA (NYXH) Q2 2024 Earnings Call Highlights: Strategic Growth and US Market Preparations
|
|
Oct 9
|
Publication relating to transparency notifications
|
|
Oct 8
|
Nyxoah Secures $27 Million to Boost U.S. Presence
|
|
Oct 7
|
Nyxoah Raises $27 Million through its At-the-Market Offering
|
|
Jul 29
|
Nyxoah to Release Second Quarter and First Half 2024 Financial Results on August 6, 2024
|
|
May 23
|
Nyxoah Announces Pricing of Offering
|
|
May 22
|
Nyxoah Announces Reduction of the Maximum Amount Available Under its At the-Market Equity Offering Program
|
|
May 22
|
Nyxoah Announces Proposed Offering of Ordinary Shares
|
|
Mar 29
|
Information on the total number of voting rights and shares
|
|
Mar 7
|
Nyxoah S.A. (NASDAQ:NYXH) Q4 2023 Earnings Call Transcript
|
|
Mar 5
|
Nyxoah SA (NYXH) Reports Q4 Loss, Misses Revenue Estimates
|
|
Mar 5
|
Nyxoah Reports Fourth Quarter and Financial Year 2023 Financial and Operating Results
|